peg-IFN alpha -2a

Small molecule

FFrench Innovative Leukemia Organisation

peg-IFN alpha -2a is one of 18 small molecule programs targeting Primary Myelofibrosis. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Primary MyelofibrosisActive, not recruiting

Primary MyelofibrosisPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

18 competitors in Primary Myelofibrosis

#DrugCompanyPhaseTrials

Jakafi

Incyte

Approved

3 2

Thalomid

Zometa

Farydak

2 5

Vonjo

OOrsoBio, Inc

Approved

—6

Ojjaara

GGlaxo Dba Glaxosmithkline

Approved

—7

Pomalyst

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Trisenox

INC424

1 10

Navitoclax

AbbVie

Phase 3

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Primary Myelofibrosis1 trial

Trial Ruxolitinib and Peg-interferon Alpha-2a Combination in Patients With Primary Myelofibrosis RUXOPeg

Completed·FFrench Innovative Leukemia Organisation·Phase 1/2·NCT02742324·37 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for peg-IFN alpha -2a. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — peg-IFN alpha -2a compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for peg-IFN alpha -2a. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — French Innovative Leukemia Organisation company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: FFrench Innovative Leukemia Organisation

peg-IFN alpha -2a

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Primary Myelofibrosis1 trial

References

Drug Info

Quick Facts

Related News